Ablative Solutions Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 42

Employees
  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $91.4M

  • Investors
  • 8

Ablative Solutions General Information

Description

Operator of a clinical-stage medical device company intended to address the significant unmet clinical need for systemic hypertension. The company has developed the Peregrine System Infusion Catheter to perform chemical renal denervation, using alcohol as the neurolytic agent, which may have substantial advantages over energy-based systems, enabling clinicians to help reduce blood pressure for patients with hypertension that is not well controlled.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Surgical Devices
Other Industries
Other Devices and Supplies
Primary Office
  • 301 Edgewater Place
  • Suite 100
  • Wakefield, MA 01880
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ablative Solutions Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 13-Jun-2022 $91.4M 00000 00000 Completed Clinical Trials - Phase 3
5. Secondary Transaction - Private 000.00 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C) 01-Mar-2017 000.00 000.00 0000 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series B) 30-Oct-2015 000.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 19-Jun-2012 $5.37M $12.3M 000.00 Completed Startup
1. Early Stage VC 10-Feb-2012 $6.92M $6.92M Completed Startup
To view Ablative Solutions’s complete valuation and funding history, request access »

Ablative Solutions Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.00
Series D1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series C 0,000,000 00.000000 00 00.0 00.00 00 00.0 00.000
Series B 2,805,392 $0.001000 8% $5.57 $8.36 1x $5.57 4.03%
Series A 1,287,757 $0.001000 8% $3.85 $5.78 1x $2.3 3.1%
To view Ablative Solutions’s complete cap table history, request access »

Ablative Solutions Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage medical device company intended to address the significant unmet clinical need for systemic
Surgical Devices
Wakefield, MA
42 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
00000000 0000000
New York, NY
000 As of 0000
000.00
000000 - 000 000.00

000000

ation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderi
00000000 0000000
Trumbull, CT
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ablative Solutions Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Angiodynamics Corporation New York, NY 000 000.00 000000 - 000 000.00
00000000000000 Corporate Backed or Acquired Trumbull, CT
0000000000 Private Equity-Backed Redwood City, CA 000 00000 000000000 00000
000000000 00000000 Venture Capital-Backed Minneapolis, MN 000 00000 00000000000 00000
00000000000 Venture Capital-Backed Plymouth, MN 00 00000 0000000000 0
You’re viewing 5 of 13 competitors. Get the full list »

Ablative Solutions Patents

Ablative Solutions Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160045257-A1 Method for selection and treatment of hypertensive patients with renal denervation Abandoned 14-Aug-2014 000000000 0
US-10517666-B2 Apparatus for effective ablation and nerve sensing associated with denervation Active 25-Oct-2013 00000000000 000
US-20190008580-A1 Apparatus for effective ablation and nerve sensing associated with denervation Granted 25-Oct-2013 00000000000 0
US-10022059-B2 Apparatus for effective ablation and nerve sensing associated with denervation Active 25-Oct-2013 00000000000 00
US-20190015002-A1 Apparatus for effective ablation and nerve sensing associated with denervation Granted 25-Oct-2013 A61B5/04001 0
To view Ablative Solutions’s complete patent history, request access »

Ablative Solutions Executive Team (11)

Name Title Board Seat Contact Info
Kathryn Rumrill President, Chief Executive Officer & Board Member
Lisa Mastromattei Vice President of Finance & Administration
Nicole Haratani Vice President of Global Clinical, Regulatory Affairs and Quality
Tim Fischell MD Co-Founder, Chief Medical Officer & Board Member
David Fischell Ph.D Co-Founder & Board Member
You’re viewing 5 of 11 executive team members. Get the full list »

Ablative Solutions Board Members (15)

Name Representing Role Since
Andrew Tochterman Ablative Solutions Board Member 000 0000
Benjamin Tsai Self Board Member 000 0000
Dale Grogan Michigan Accelerator Fund 1 Board Member 000 0000
David Fischell Ph.D Self Co-Founder & Board Member 000 0000
Geoff Pardo Gilde Healthcare Partners Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Ablative Solutions Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ablative Solutions Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gilde Healthcare Partners Venture Capital Minority 000 0000 000000 0
Invus Opportunities Venture Capital Minority 000 0000 000000 0
Dempsey Ventures PE/Buyout Minority 000 0000 000000 0
GlobalLink1 Capital PE/Buyout Minority 000 0000 000000 0
BioStar Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »